• BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

    Source: Nasdaq GlobeNewswire / 23 Feb 2024 06:00:00   America/Chicago

    N/A
Share on,